Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tiotropium bromide.

Karen M Hvizdos1, Karen L Goa

  • 1Adis International Limited, Auckland, New Zealand.

Drugs
|May 16, 2002
PubMed
Summary
This summary is machine-generated.

Tiotropium bromide, a long-acting anticholinergic bronchodilator, improves lung function and reduces exacerbations in chronic obstructive pulmonary disease (COPD) patients. Once-daily tiotropium offers significant benefits for COPD management with good tolerability.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Erratum to: Maclobemide.

Drugs·2017
Same author

Erratum to: Moclobemide.

Drugs·2017
Same author

Erratum to: Cyclosporin: A Review of its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Use in Immunoregulatory Disorders.

Drugs·2017
Same author

Transdermal ethinylestradiol/norelgestromin: a review of its use in hormonal contraception.

Treatments in endocrinology·2005
Same author

Spotlight on insulin aspart in type 1 and 2 diabetes mellitus.

Treatments in endocrinology·2005
Same author

Spotlight on rosiglitazone in the management of type 2 diabetes mellitus.

Treatments in endocrinology·2005

Area of Science:

  • Pharmacology
  • Respiratory Medicine

Background:

  • Tiotropium bromide is an anticholinergic bronchodilator targeting muscarinic receptors.
  • Its slow dissociation from M3 receptors in bronchial smooth muscle contributes to a long duration of action, enabling once-daily dosing.

Purpose of the Study:

  • To evaluate the efficacy and safety of tiotropium bromide in patients with chronic obstructive pulmonary disease (COPD).

Main Methods:

  • Comparative trials of tiotropium 18 mcg once daily versus placebo, ipratropium 40 mcg four times daily, and salmeterol 50 mcg twice daily.
  • Assessment of lung function, COPD exacerbations, rescue medication use, dyspnea perception, and health-related quality of life.

Main Results:

  • Tiotropium significantly improved lung function compared to placebo, ipratropium, and salmeterol.

Related Experiment Videos

  • Reduced incidence of COPD exacerbations and lower rescue medication use were observed with tiotropium versus placebo or ipratropium.
  • Significant improvements in dyspnea and quality of life were noted with tiotropium compared to placebo, salmeterol, and ipratropium.
  • No evidence of tachyphylaxis during 1-year treatment.

    • Conclusions:

    • Tiotropium bromide is an effective and well-tolerated once-daily treatment for COPD, improving lung function, reducing exacerbations, and enhancing quality of life.
    • Dry mouth is the most common side effect, reported in 10-16% of patients.